Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline
Executive Summary
Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.
You may also be interested in...
Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Merck’s Ervebo Becomes World’s First Approved Ebola Vaccine
Merck Sharp & Dohme will begin manufacturing licensed doses of Ervebo in Germany and will continue to send investigational vaccine doses to Democratic Republic of Congo.
Keeping Track: Biosimilars, Novel Approvals, And Ebola
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.